Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $334.07 | 4 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Vital Connect, Inc | $287.51 | 1 | $0 (2022) |
| AbbVie Inc. | $31.52 | 2 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $15.04 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $18.86 | 1 | AbbVie Inc. ($18.86) |
| 2022 | $287.51 | 1 | Vital Connect, Inc ($287.51) |
| 2021 | $27.70 | 2 | AstraZeneca Pharmaceuticals LP ($15.04) |
All Payment Transactions
4 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/05/2023 | AbbVie Inc. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $18.86 | General |
| Category: NEUROSCIENCE | ||||||
| 07/27/2022 | Vital Connect, Inc | — | Food and Beverage | Cash or cash equivalent | $287.51 | General |
| 10/26/2021 | AbbVie Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $12.66 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/14/2021 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $15.04 | General |
| Category: Cardiovascular and Metabolism | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 416 | 486 | $75,752 | $27,963 |
| 2022 | 7 | 374 | 413 | $55,757 | $21,642 |
| 2021 | 1 | 31 | 53 | $5,300 | $2,884 |
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 250 | 308 | $64,064 | $23,655 | 36.9% |
| 87428 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus and influenza | Office | 2023 | 31 | 32 | $3,776 | $1,596 | 42.3% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2023 | 28 | 31 | $2,387 | $1,073 | 45.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 12 | 12 | $1,752 | $563.44 | 32.2% |
| 87880 | Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | Office | 2023 | 27 | 30 | $930.00 | $469.80 | 50.5% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 11 | 12 | $1,356 | $219.80 | 16.2% |
| 90471 | Administration of vaccine | Office | 2023 | 11 | 11 | $495.00 | $141.70 | 28.6% |
| 81002 | Urinalysis, manual test | Office | 2023 | 34 | 37 | $407.00 | $123.10 | 30.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 12 | 13 | $585.00 | $120.96 | 20.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 135 | 150 | $31,200 | $12,466 | 40.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 102 | 107 | $15,622 | $5,229 | 33.5% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2022 | 52 | 54 | $4,158 | $2,293 | 55.2% |
| 87428 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus and influenza | Office | 2022 | 25 | 25 | $2,950 | $758.93 | 25.7% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2022 | 16 | 32 | $992.00 | $520.67 | 52.5% |
| 87880 | Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | Office | 2022 | 17 | 17 | $527.00 | $277.52 | 52.7% |
| 81002 | Urinalysis, manual test | Office | 2022 | 27 | 28 | $308.00 | $95.90 | 31.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 31 | 53 | $5,300 | $2,884 | 54.4% |
About Dr. Scott Bland, DO
Dr. Scott Bland, DO is a Family Medicine healthcare provider based in Fayetteville, Arkansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/06/2018. The National Provider Identifier (NPI) number assigned to this provider is 1285131383.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Scott Bland, DO has received a total of $334.07 in payments from pharmaceutical and medical device companies, with $18.86 received in 2023. These payments were reported across 4 transactions from 3 companies. The most common payment nature is "Food and Beverage" ($334.07).
As a Medicare-enrolled provider, Bland has provided services to 821 Medicare beneficiaries, totaling 952 services with total Medicare billing of $52,489. Data is available for 3 years (2021–2023), covering 17 distinct procedure/service records.
Practice Information
- Specialty Family Medicine
- Location Fayetteville, AR
- Active Since 04/06/2018
- Last Updated 06/26/2024
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1285131383
Products in Payments
- QULIPTA (Drug) $18.86
- LOKELMA (Drug) $15.04
- DALVANCE (Drug) $12.66
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Fayetteville
Dr. Daniel Uba, Md/Internal Medicine, MD/INTERNAL MEDICINE
Family Medicine — Payments: $127,961
John Ray, M.d, M.D
Family Medicine — Payments: $18,165
William Hughes, M.d, M.D
Family Medicine — Payments: $12,858
Mark Bonner, Md, MD
Family Medicine — Payments: $12,578
Richard Cline, D.o, D.O
Family Medicine — Payments: $12,163
Dr. William Adcox, Md, MD
Family Medicine — Payments: $12,048